Bio-Rad Laboratories, Inc.
BIOB
NYSE
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 2.59B | 2.58B | 2.56B | 2.55B | 2.54B |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 2.59B | 2.58B | 2.56B | 2.55B | 2.54B |
| Cost of Revenue | 1.25B | 1.24B | 1.21B | 1.19B | 1.17B |
| Gross Profit | 1.34B | 1.34B | 1.35B | 1.36B | 1.37B |
| SG&A Expenses | 838.90M | 835.30M | 822.50M | 817.80M | 808.50M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 2.35B | 2.35B | 2.32B | 2.31B | 2.28B |
| Operating Income | 243.20M | 232.80M | 242.30M | 240.30M | 261.20M |
| Income Before Tax | 222.30M | 995.50M | -842.60M | 450.10M | -2.75B |
| Income Tax Expenses | 53.50M | 235.60M | -166.70M | 130.90M | -586.10M |
| Earnings from Continuing Operations | 168.80 | 759.90 | -675.90 | 319.20 | -2.16K |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 168.80M | 759.90M | -675.90M | 319.20M | -2.16B |
| EBIT | 243.20M | 232.80M | 242.30M | 240.30M | 261.20M |
| EBITDA | 411.40M | 398.20M | 404.40M | 397.10M | 413.80M |
| EPS Basic | 6.11 | 27.95 | -24.30 | 11.77 | -76.17 |
| Normalized Basic EPS | 6.49 | 6.57 | 6.39 | 6.25 | 6.76 |
| EPS Diluted | 6.07 | 27.91 | -24.31 | 11.73 | -76.20 |
| Normalized Diluted EPS | 6.49 | 6.56 | 6.39 | 6.25 | 6.76 |
| Average Basic Shares Outstanding | 108.08M | 109.07M | 110.09M | 111.11M | 112.28M |
| Average Diluted Shares Outstanding | 108.12M | 109.12M | 110.10M | 111.17M | 112.33M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |